Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Page 1
Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy.
Preisser F, Wang N, Abrams-Pompe RS, Chun FK, Graefen M, Huland H, Tilki D. Preisser F, et al. Among authors: huland h. Urol Oncol. 2022 Apr;40(4):161.e9-161.e14. doi: 10.1016/j.urolonc.2021.11.019. Epub 2021 Dec 30. Urol Oncol. 2022. PMID: 34973856
BACKGROUND: Organ-confined prostate cancer (CaP) at radical prostatectomy (RP) is associated with good long-term outcomes. However, information for aggressive Gleason organ-confined CaP is scant. To investigate the impact of Gleason grade group (GG) 4-5 on long-term …
BACKGROUND: Organ-confined prostate cancer (CaP) at radical prostatectomy (RP) is associated with good long-term outcomes. However, i …
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Xiang M, et al. Among authors: huland h. JAMA Netw Open. 2021 Dec 1;4(12):e2138550. doi: 10.1001/jamanetworkopen.2021.38550. JAMA Netw Open. 2021. PMID: 34902034 Free PMC article.
IMPORTANCE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implica …
IMPORTANCE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlo …
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center.
Würnschimmel C, Wenzel M, Wang N, Tian Z, Karakiewicz PI, Graefen M, Huland H, Tilki D. Würnschimmel C, et al. Among authors: huland h. Urol Oncol. 2021 Dec;39(12):830.e17-830.e26. doi: 10.1016/j.urolonc.2021.04.031. Epub 2021 Jun 4. Urol Oncol. 2021. PMID: 34092484
INTRODUCTION: Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are under-reported. ...
INTRODUCTION: Long-term outcomes of prostate cancer (CaP) patients treated with radical prostatectomy (RP) from European cohorts are …
Impact of the estimated blood loss during radical prostatectomy on functional outcomes.
Preisser F, Pompe RS, Salomon G, Rosenbaum C, Graefen M, Huland H, Karakiewicz PI, Tilki D. Preisser F, et al. Among authors: huland h. Urol Oncol. 2019 May;37(5):298.e11-298.e17. doi: 10.1016/j.urolonc.2019.01.006. Epub 2019 Mar 8. Urol Oncol. 2019. PMID: 30857988
MRLM predicting continence in ORP revealed that high BL was an independent predictor for 7-days and mid-term: ORs were 0.80 (P = 0.04) and 0.66 (P = 0.002). Moreover, high BL was an independent predictor for 7-days continence in RALP: OR were 0.68 (P = 0.009). ...
MRLM predicting continence in ORP revealed that high BL was an independent predictor for 7-days and mid-term: ORs were 0.80 (P = 0.04 …
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D. Preisser F, et al. Among authors: huland h. Eur Urol. 2019 Jul;76(1):106-114. doi: 10.1016/j.eururo.2019.01.048. Epub 2019 Feb 14. Eur Urol. 2019. PMID: 30772034
OBJECTIVE: To investigate the impact of persistent PSA at 6wk after RP on long-term oncologic outcomes and to assess patient characteristics associated with persistent PSA. ...
OBJECTIVE: To investigate the impact of persistent PSA at 6wk after RP on long-term oncologic outcomes and to assess patient characte …
The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy.
Tilki D, Preisser F, Karakiewicz P, Shariat SF, Graefen M, Huland H, Chun FK, Pompe RS. Tilki D, et al. Among authors: huland h. World J Urol. 2018 Aug;36(8):1247-1253. doi: 10.1007/s00345-018-2274-y. Epub 2018 Mar 26. World J Urol. 2018. PMID: 29582100
PURPOSE: To assess the impact of prolonged catheterization time on 1-week (short-term), 3-month (intermediate-term) and 1-year (long-term) UC. METHODS: Between 2008 and 2015, 6918 men underwent RP by four high-volume surgeons. ...CONCLUSIONS: While longer cat …
PURPOSE: To assess the impact of prolonged catheterization time on 1-week (short-term), 3-month (intermediate-term) and 1-year …
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D. Pompe RS, et al. Among authors: huland h. Prostate. 2018 Jun;78(9):676-681. doi: 10.1002/pros.23511. Epub 2018 Mar 23. Prostate. 2018. PMID: 29570821
BACKGROUND: Rates of metastatic progression (MP) and prostate cancer mortality (PCSM) are variable after biochemical recurrence (BCR) in patients who underwent radical prostatectomy (RP). To describe long-term oncological outcomes of BCR patients and to analyze risk factor …
BACKGROUND: Rates of metastatic progression (MP) and prostate cancer mortality (PCSM) are variable after biochemical recurrence (BCR) in pat …
61 results